A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone ... We look forward to sharing full results ...

CAR T-cell therapy, a cancer immunotherapy treatment for multiple myeloma, utilises cell-base. gene therapy where a patient's T cells undergo genetic modification to enhance cancer cell ...